MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1

被引:20
作者
Yao, Yanfen [1 ]
Li, Qiaorong [1 ]
Wang, Hong [2 ]
机构
[1] Shandong Prov Third Hosp, Dept Intens Care Unit, Jinan, Shandong, Peoples R China
[2] Shandong Prov Third Hosp, Dept Gen Surg, 12 Cent Wuying Hill Rd, Jinan 250031, Shandong, Peoples R China
关键词
MiR-216b; SRPK1; colorectal cancer; proliferation; migration; invasion; RANDOMIZED CLINICAL-TRIAL; BIOMARKERS;
D O I
10.2147/OTT.S161835
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: MiR-216b has been reported to be involved in the development of some cancers, however, the role of miR-216b in colorectal cancer (CRC) remains unclear. Purpose: This study aimed to investigate the mechanism underlying miR-216b-induced CRC development. Methods: We detected the expression of miR-216b in 80 cases of CRC tissues and cell lines, and further analyzed the association between miR-216b and clinical pathological indicators as well as prognosis. In vitro, the miR-216b overexpression cell model was established for further functional assay. Results: We demonstrated that miR-216b in CRC tissues and cell lines was markedly decreased compared with corresponding adjacent normal tissues and colonic mucosal epithelial cell line, and was obviously associated with the TNM stage, lymph node metastases, and poor overall survival as well as recurrence-free survival. Furthermore, we found that miR-216b inhibited cell proliferation, cell cycle, migration, and invasion by targeting 3'-UTR of SRPK1. Besides, SRPK1 over-expression reversed miR-216b-inhibited cell proliferation, migration and invasion, while SRPK1 inhibition aggravated these effects. Conclusions: We identified that miR-216b suppresses colorectal cancer proliferation, migration and invasion by targeting SRPK1, which shed light on how miR-216b functions in CRC pathogenesis.
引用
收藏
页码:1671 / 1681
页数:11
相关论文
共 23 条
[1]   Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease [J].
Batson, Jennifer ;
Toop, Hamish D. ;
Redondo, Clara ;
Babaei-Jadidi, Roya ;
Chaikuad, Apirat ;
Wearmouth, Stephen F. ;
Gibbons, Brian ;
Allen, Claire ;
Tallant, Cynthia ;
Zhang, Jingxue ;
Du, Chunyun ;
Hancox, Jules C. ;
Hawtrey, Tom ;
Da Rocha, Joana ;
Griffith, Renate ;
Knapp, Stefan ;
Bates, David O. ;
Morris, Jonathan C. .
ACS CHEMICAL BIOLOGY, 2017, 12 (03) :825-832
[2]   The many faces of SRPK1 [J].
Bullock, Nicholas ;
Oltean, Sebastian .
JOURNAL OF PATHOLOGY, 2017, 241 (04) :437-440
[3]  
Chen XX, 2017, AM J CANCER RES, V7, P2051
[4]   Culture adaptation of malaria parasites selects for convergent loss-of-function mutants [J].
Claessens, Antoine ;
Affara, Muna ;
Assefa, Samuel A. ;
Kwiatkowski, Dominic P. ;
Conway, David J. .
SCIENTIFIC REPORTS, 2017, 7
[5]   miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma [J].
Deng, Min ;
Tang, Hailin ;
Zhou, Yanhong ;
Zhou, Ming ;
Xiong, Wei ;
Zheng, Ying ;
Ye, Qiurong ;
Zeng, Xi ;
Liao, Qianjin ;
Guo, Xiaofang ;
Li, Xiaoling ;
Ma, Jian ;
Li, Guiyuan .
JOURNAL OF CELL SCIENCE, 2011, 124 (17) :2997-3005
[6]  
Endo K, 2013, BIOMED RES-TOKYO, V34, P179
[7]  
Karmakar S, SEMIN CANC BIOL
[8]   MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway [J].
Liu, F-y ;
Zhou, S-j ;
Deng, Y-l ;
Zhang, Z-y ;
Zhang, E-l ;
Wu, Z-b ;
Huang, Z-y ;
Chen, X-p .
CELL DEATH & DISEASE, 2015, 6 :e1670-e1670
[9]   A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and Advanced Adenoma [J].
Liu, K. L. ;
Luo, J. L. ;
Wu, J. ;
Wang, Y. D. ;
Fan, H. J. .
CLINICAL LABORATORY, 2017, 63 (11-12) :1949-1953
[10]   MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1 [J].
Liu, Y. ;
Niu, Z. ;
Lin, X. ;
Tian, Y. .
CANCER GENE THERAPY, 2017, 24 (05) :208-214